What is the mechanism of action for reversible AChE inhibitors?

Reversible AChE inhibitors work by preventing the breakdown of acetylcholine (ACh) in the synaptic cleft. Acetylcholine is a neurotransmitter that plays a vital role in transmitting signals in the nervous system, particularly in cholinergic pathways. When these inhibitors are administered, they bind to the acetylcholinesterase (AChE) enzyme, the enzyme responsible for hydrolyzing acetylcholine into acetate and choline. As a result, the activity of AChE is reduced, leading to an accumulation of acetylcholine at synapses. This increased level of ACh enhances cholinergic neurotransmission, which is beneficial in various clinical settings, such as the treatment of myasthenia gravis or Alzheimer's disease, where cholinergic signaling is impaired.

The other choices involve different mechanisms not related to the action of AChE inhibitors. Inhibiting dopamine receptors targets dopaminergic pathways, blocking serotonin uptake affects serotonergic transmission, and decreasing calcium absorption pertains to different physiological processes related to calcium homeostasis but does not connect to the cholinergic system or AChE inhibition.